In January 2020 approximately 500 world opinion leaders, academics, practitioners, and patient representatives will meet in London for four days to share state-of-the-art knowledge on epidermolysis bullosa (EB). As this is the first time that such a comprehensive gathering will come together, it presents an exciting and unique opportunity for companies to get involved and sponsor the event. Together we can do more!
We are excited to have Abeona’s support for the 1st Global Congress on EB! Read below to find out more about our much appreciated sponsor:
1. Tell us a bit about your company/organisation.
Abeona is a fully-integrated leader in gene and cell therapy with expertise in R&D, manufacturing, and discovery. We have a team of almost 100 employees working to discover and develop transformative therapies for serious rare genetic diseases that have no existing treatments.
2. What is your mission or goal as a company/organisation?
Our mission is rooted in our origins, as our company was founded in partnership with patient advocates. Working together to deliver gene and cell therapies for people impacted by serious diseases.
3. How is your company/organisation involved with EB?
We are developing EB-101, a novel gene-corrected cell therapy designed to treat the type of wounds that lead to devastating and debilitating consequences for RDEB patients. We are planning to initiate a Phase 3 clinical trial in 4Q 2019.
4. What are you looking forward to about EB 2020? Why did you decide to get involved?
EB2020 is an incredible opportunity, bringing together the world’s foremost experts in EB, including many advocates and families impacted by the disease. We look forward to learning from these experts, sharing our own knowledge, and exploring ways to accomplish goals together such as significantly improving the quality of life of people impacted by RDEB.
5. What does the future of EB look like to your company/organisation?
We envision a world through gene and cell therapies, where cure is the new standard of care. We are encouraged that these therapies will transform the quality of life for people living with EB by restoring normal skin function. This requires supporting the entire patient ecosystem, such as ensuring comprehensive care for RDEB patients and ensuring access to novel therapies.
For additional information about Abeona, please visit: https://www.abeonatherapeutics.com/
For information about sponsorship, please visit: https://ebworldcongress.org/sponsors/sponsorship/